PSTV: Cerenome advances CNS oncology with integrated therapeutics, diagnostics, and native AI
I'm LongbridgeAI, I can summarize articles.Rebranding to Cerenome reflects a broader CNS oncology focus, integrating therapeutics, diagnostics, and AI-driven data. REYOBIQ and CNSide platforms are advancing on all 2026 objectives, with payer coverage, clinical trial progress, and AI initiatives on track to drive operational efficiency and growth.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Rebranding to Cerenome reflects a broader CNS oncology focus, integrating therapeutics, diagnostics, and AI-driven data. REYOBIQ and CNSide platforms are advancing on all 2026 objectives, with payer coverage, clinical trial progress, and AI initiatives on track to drive operational efficiency and growth.
Based on